Clinical evaluation of an automatic blood-pressure monitoring device.

Reliability and reproducibility of an automatic ambulatory blood pressure recorder (ICR-5200, Squibb) were tested on 45 subjects (24 normotensives and 21 hypertensives) aged 32-64 (mean age 49). Of 6,566 recordings, 2,376 measurements were cross-checked with a Riva Rocci sphygmomanometer in supine, standing, or sitting position at the beginning and at the end of a 24-hour monitoring period. Moreover, in 11 normotensives and in 11 hypertensives, cross-checking was performed during a cycloergometer effort test.

Transcutaneous oximetry in evaluation of the initial peripheral artery disease in diabetics.

This study was performed to evaluate the reliability of transcutaneous oximetry as compared with strain gauge plethysmography and with Doppler in the assessment of the initial peripheral vascular disease in diabetics who are still asymptomatic. Twenty-five diabetics (38 lower extremities) with different degrees of peripheral vascular disease, classified according to Fontaine, were investigated. Ten healthy subjects (16 lower extremities) served as controls.

Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.

Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2 (PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2 and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2 studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.

Age related changes of platelet prostacyclin receptors in humans.

Platelet receptors for PGI2 were investigated in eighteen healthy volunteers divided in two classes of age: nine were 18-40 years old and nine were 41-65 years old. PGI2 platelet receptors were found to decrease significantly with age; the young subjects had 106 +/- 16 (mean +/- SD) high affinity receptors/platelet and 3509 +/- 529 low affinity receptors/platelet whereas the old subjects had 86 +/- 14 high affinity receptors/platelet (P less than 0.02) and 2471 +/- 640 low affinity receptors/platelet (P less than 0.

Decreased number of PGD2 binding sites on platelets from patients with type IIa hyperlipoproteinemia.

Platelets from patients with familial hypercholesterolemia (type IIa hyperlipoproteinemia), a condition associated with a high prevalence of atherosclerosis and its ischemic complications, are claimed to be hyperresponsive to aggregating stimuli. We investigated the platelet responsiveness to and the binding of PGD2, a potent endogenous inhibitor of platelet aggregation via stimulation of adenylate cyclase, in a group of 7 patients affected by IIa hyperlipoproteinemia (IIa HLP) and in a control group of 10 healthy subjects. Inhibition by PGD2 of ADP-induced platelet aggregation was significantly lower in IIa HLP patients than in controls.

Reduction in prostacyclin platelet receptors in active spontaneous angina.

The number and affinity of binding sites for tritiated prostacyclin (PGI2) in platelets were investigated in twenty-eight patients with spontaneous angina (fourteen in the active and fourteen in the inactive phase) and in nine healthy controls of similar age. Active-phase patients had significantly lower numbers of both classes of platelet PGI2 receptors (high affinity and low affinity) than controls or inactive-phase patients. In contrast, the affinity for PGI2 was not significantly different in the three groups.